protein

TAR

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about TAR: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

161Connections

30Hypotheses

9Analyses

50Outgoing

50Incoming

11Experiments

15Debates

Summary

Page for TAR DNA-Binding Protein 43 (TDP-43)

View on Wiki →

No AI portrait yet

🔬 Protein Info

Gene Symbol	TAR
Aliases	TDP-43
Chromosome	1p36.22
Molecular Weight	44.7 kDa
Amino Acids	414 aa
Pathways	oxidative stress response, UNFOLDED PROTEIN RESPONSE, UBIQUITIN-PROTEASOME
GeneCards	TAR
Human Protein Atlas	TAR
Associated Diseases	ALS, Alzheimer, dementia, frontotemporal, neurodegeneration
Known Drugs/Compounds	rapamycin
Interactions	ALS, AMPK, AR, ATG, ATXN2, BAG3
KG Connections	161 knowledge graph edges
Databases	GeneCards UniProt NCBI Gene HPA STRING

Wiki Pages (13)

Knowledge base pages for this entity

Synaptic Therapy Alzheimer's Research Trial (START): A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease (NCT05531656)

clinical · 1758 words

→

SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment

clinical · 1457 words

→

Pathway Diagram

graph TD
    TAR["TAR"]
    TDP_43(["TDP-43"])
    TAR -->|"interacts_with"| TDP_43
    WAS(["WAS"])
    TAR -->|"co_discussed"| WAS
    FUS(["FUS"])
    TAR -->|"interacts_with"| FUS
    RNA(["RNA"])
    TAR -->|"regulates"| RNA
    GENES(["GENES"])
    TAR -->|"regulates"| GENES
    TBK1(["TBK1"])
    TAR -->|"regulates"| TBK1
    DNA(["DNA"])
    DNA -->|"co_discussed"| TAR
    NEAT1(["NEAT1"])
    NEAT1 -->|"co_discussed"| TAR
    NEURON(["NEURON"])
    NEURON -->|"co_discussed"| TAR
    style TAR fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#4fc3f7

Outgoing (59)

Target	Relation	Type	Str
neurodegeneration	interacts_with	disease	0.85
oxidative stress response	participates_in	pathway	0.85
ALS	interacts_with	disease	0.75
TDP-43	regulates	gene	0.75
TARDBP	regulates	gene	0.75
frontotemporal dementia	interacts_with	disease	0.75
TFEB	activates	gene	0.60
TPP1	activates	gene	0.60
TREH	activates	gene	0.60
Parkinson's disease	activates	disease	0.60
neurodegeneration	activates	disease	0.60
ALS	activates	disease	0.60
Huntington's disease	activates	disease	0.60
autophagy pathway	participates_in	pathway	0.60
Huntington's disease	interacts_with	disease	0.60
dementia	associated_with	disease	0.60
frontotemporal	associated_with	disease	0.60
TARDBP	activates	gene	0.60
ubiquitin-proteasome	participates_in	pathway	0.60
TAX1BP1	interacts_with	gene	0.60
TBK1	activates	gene	0.60
VCP	activates	gene	0.60
frontotemporal dementia	activates	disease	0.60
Notch signaling	participates_in	pathway	0.60
TDP43	regulates	gene	0.60
WDR41	activates	gene	0.60
ULK1	activates	gene	0.60
VCP	interacts_with	gene	0.60
ALS	regulates	disease	0.60
VCP	regulates	gene	0.60
TMEM106B	interacts_with	gene	0.60
ALS	associated_with	disease	0.60
neurodegeneration	associated_with	disease	0.60
Alzheimer	associated_with	disease	0.60
neurodegeneration	regulates	disease	0.60
TDP43	interacts_with	gene	0.60
Alzheimer's disease	activates	disease	0.60
DAM microglia	expressed_in	cell_type	0.55
stem cells	expressed_in	cell_type	0.55
neurons	expressed_in	cell_type	0.55
TGM2	interacts_with	gene	0.55
TARDBP	interacts_with	gene	0.55
Parkinson's disease	interacts_with	disease	0.55
Alzheimer's disease	interacts_with	disease	0.55
UNC13A	regulates	gene	0.50
VIPR1	regulates	protein	0.50
RBPJL	regulates	gene	0.50
TDP-43	interacts_with	protein	0.50
WAS	co_discussed	protein	0.50
FUS	interacts_with	gene	0.50

Incoming (102)

Source	Relation	Type	Str
DNA	activates	gene	0.90
DNA	interacts_with	gene	0.85
RNA	activates	gene	0.80
GRN	interacts_with	gene	0.80
ALS	interacts_with	gene	0.75
DNA	regulates	gene	0.75
RNA	regulates	gene	0.75
PGRN	interacts_with	gene	0.70
RNA	interacts_with	gene	0.65
FUS	interacts_with	gene	0.60
STUB1	activates	gene	0.60
rapamycin	targets	drug	0.60
MAPT	activates	gene	0.60
FTLD	interacts_with	gene	0.60
STING	activates	gene	0.60
ALS	activates	gene	0.60
AR	activates	gene	0.60
ATG	activates	gene	0.60
BAG3	activates	gene	0.60
BCL2	activates	gene	0.60
BECN1	activates	gene	0.60
CTSB	activates	gene	0.60
GAPDH	activates	gene	0.60
GLA	activates	gene	0.60
HSPA8	activates	gene	0.60
HSPB8	activates	gene	0.60
LAMP1	activates	gene	0.60
LAMP2A	activates	gene	0.60
LGALS3	activates	gene	0.60
MAP1LC3B	activates	gene	0.60
MCOLN1	activates	gene	0.60
MTOR	activates	gene	0.60
PPARGC1A	activates	gene	0.60
PPP3CB	activates	gene	0.60
SOD1	activates	gene	0.60
SQSTM1	activates	gene	0.60
STIP1	activates	gene	0.60
ATXN2	activates	gene	0.60
SMCR8	activates	gene	0.60
STX17	activates	gene	0.60
NTN1	interacts_with	gene	0.60
NTN3	interacts_with	gene	0.60
PTN	interacts_with	gene	0.60
SNRNP70	interacts_with	gene	0.60
NEAT1	interacts_with	gene	0.60
CHMP2B	activates	gene	0.60
LC3	activates	gene	0.60
MAP1LC3	activates	gene	0.60
PINK1	activates	gene	0.60
PTEN	activates	gene	0.60

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Closed-loop transcranial focused ultrasound targeting EC-II	0.948	Alzheimer's disease	Circuit-level neural dynamics in neurode
Closed-loop optogenetic targeting PV interneurons to restore	0.944	Alzheimer's disease	Circuit-level neural dynamics in neurode
Closed-loop focused ultrasound targeting CA1 PV interneurons	0.927	Alzheimer's disease	Circuit-level neural dynamics in neurode
Closed-loop transcranial focused ultrasound targeting EC-II	0.922	Alzheimer's disease	Circuit-level neural dynamics in neurode
Closed-loop focused ultrasound targeting EC-II SST interneur	0.900	Alzheimer's disease	Circuit-level neural dynamics in neurode

Closed-loop tACS targeting EC-II SST interneurons to block t	0.896	Alzheimer's disease	Circuit-level neural dynamics in neurode
Multi-Target Hypothesis: Aβ-Induced Cholinergic Damage is Pa	0.887	-	Do β-amyloid plaques and neurofibrillary
Closed-loop focused ultrasound targeting EC-II PV interneuro	0.863	Alzheimer's disease	Circuit-level neural dynamics in neurode
Closed-loop tACS targeting EC-II PV interneurons to suppress	0.857	Alzheimer's disease	Circuit-level neural dynamics in neurode
Circadian Glymphatic Entrainment via Targeted Orexin Recepto	0.841	neurodegeneration	Perivascular spaces and glymphatic clear
Closed-loop tACS targeting EC-II parvalbumin interneurons to	0.831	Alzheimer's disease	Circuit-level neural dynamics in neurode
Real-time gamma-guided transcranial focused ultrasound targe	0.827	Alzheimer's disease	Circuit-level neural dynamics in neurode
Beta-frequency entrainment therapy targeting PV interneuron-	0.827	Alzheimer's disease	Circuit-level neural dynamics in neurode
Targeting the Mechanistic Link Between AQP4 Dysfunction and	0.803	neurodegeneration	View
pH-Sensitive Bispecific Antibody Targeting Transferrin Recep	0.800	neurodegeneration	Blood-brain barrier antibody transport m
Closed-loop transcranial focused ultrasound targeting CA1 PV	0.797	Alzheimer's disease	Circuit-level neural dynamics in neurode
Selective APOE4 Degradation via Proteolysis Targeting Chimer	0.795	neurodegeneration	APOE4 structural biology and therapeutic
Targeting SASP-Complement Amplification Through HIF-1α Downs	0.793	neurodegeneration	What molecular mechanism causes VCP muta
Closed-loop tACS targeting entorhinal cortex layer II SST in	0.784	Alzheimer's disease	Circuit-level neural dynamics in neurode
Targeted APOE4-to-APOE3 Base Editing Therapy	0.758	neurodegeneration	APOE4 structural biology and therapeutic
VHH-Fc Fusion Constructs with Separate BBB-Targeting Moiety	0.750	neurodegeneration	Blood-brain barrier antibody transport m
TREM2-APOE4 Co-targeting — Simultaneous Correction of Lipid	0.741	Alzheimer's disease	TREM2 agonism vs antagonism in DAM micro
Phase-Separated Organelle Targeting	0.729	neurodegeneration	Microglia-astrocyte crosstalk amplificat
Metabolic Switch Targeting for A1→A2 Repolarization	0.726	neurodegeneration	Astrocyte reactivity subtypes in neurode
Proteostasis Enhancement via APOE Chaperone Targeting	0.724	neurodegeneration	Mechanistic role of APOE in neurodegener
TDP-43 condensation thermodynamics as a therapeutic target a	0.710	neuroscience	How can subcellular compartmentalization
Matrix Stiffness Normalization via Targeted Lysyl Oxidase In	0.709	neurodegeneration	Perivascular spaces and glymphatic clear
Targeted Butyrate Supplementation for Microglial Phenotype M	0.700	neurodegeneration	What are the mechanisms by which gut mic
m6A RNA Modification as Address Code for Granule Targeting	0.700	neurodegeneration	What determines the specificity of RNA-p
Pericyte-targeted senolysis or senomorphic therapy will bene	0.700	neurodegeneration	Does pericyte senescence drive BBB break

Mentioning Analyses (9)

Scientific analyses that reference this entity

Does APOE4 drive tau propagation

neurodegeneration | 2026-04-16 | 0 hypotheses

Does APOE4 drive tau propagation

neurodegeneration | 2026-04-15 | 0 hypotheses

test debate

neurodegeneration | 2026-04-15 | 0 hypotheses

Do these mechanistic hypotheses from the SEA-AD Atlas bundle explain layer-speci

neurodegeneration | 2026-04-10 | 0 hypotheses

Do these mechanistic hypotheses explain layer-specific synaptic vulnerability in

neurodegeneration | 2026-04-10 | 0 hypotheses

Experiments (11)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Plant-based dietary patterns and Alzheimer's disease risk in multiethn	clinical	Alzheimer's disease and relate	0.950	0.00	human patients	proposed	N/A
CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co	clinical	Alzheimer's Disease	0.900	0.50	aortic endothelial cells	proposed	$6,550,000
s:** - Test tau spreading in AQP4 knockout vs wild-type mice with PSP/	falsification	Neurodegeneration	0.400	0.50	mouse	proposed	$260,000
Circadian-Vascular-Metabolic Syndrome (CVMS) Intervention Trial	clinical	Neurodegeneration	0.400	0.50	human	proposed	$3,900,000
DLB Cognitive Fluctuation Mechanism Experiment	clinical	Neurodegeneration	0.400	0.50	human	proposed	$6,550,000
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$5,460,000
Non-Motor Symptom Progression in Parkinson's Disease — Mechanisms and	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$5,460,000
NPH Glymphatic System Interaction Experiment	clinical	Neurodegeneration	0.400	0.50	human	proposed	$5,460,000
Sleep and Circadian Dysfunction as Driver of Neurodegeneration	clinical	Neurodegeneration	0.400	0.50	human	proposed	$5,460,000
Sleep Disruption and Alzheimer's Disease — mechanism and intervention	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
Sleep and Respiratory Network Interaction in ALS — Experiment Design	clinical	ALS	0.400	0.50	human	proposed	$5,460,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Combined effects of HCRTR1/2 gene variants and non-genetic factors on sleep-wake [PMID:40439868]	Zheng Z, Xue F, Wang H, Gu Q, Hu R, Li X	Pharmacol Rep	2025	1
Genetic determinants of daytime napping and effects on cardiometabolic health. [PMID:33568662]	Dashti HS, Daghlas I, Lane JM, Huang Y,	Nat Commun	2021	1
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. [PMID:34052813]	Sun Y, Tisdale RK, Kilduff TS	Front Neurol Neurosci	2021	1
Sleep drives metabolite clearance from the adult brain. [PMID:24136970]	Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Th	Science	2013	1
Signal transduction, dimerization, and therapeutic targeting of Orexin and recep [PMID:41383480]	Zhang S, Wang P, Ji B, Shao Y, Hou S et	Front Pharmacol	2025	0
Increased Neuronal Expression of the Early Endosomal Adaptor APPL1 Replicates Al [PMID:40514243]	Jiang Y, Sachdeva K, Goulbourne CN, Berg	The Journal of neuroscience :	2025	0
Bioinformatic analysis of neuropeptide related genes in patients diagnosed with [PMID:39437604]	Yay F, Ayan D	Comput Biol Med	2024	0
Effects of Paradoxical Sleep Deprivation on MCH and Hypocretin Systems. [PMID:39698172]	Agamme ALDA, Tufik S, Torterolo P, D'Alm	Sleep science (Sao Paulo, Braz	2024	0
P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting [PMID:38513667]	Zhang D, Zhang W, Ming C, Gao X, Yuan H,	Neuron	2024	0
The necroptosis cell death pathway drives neurodegeneration in Alzheimer's disea [PMID:38852117]	Balusu S, De Strooper B	Acta neuropathologica	2024	0
Blast Exposure Induces Acute Alterations in Circadian Clock Genes in the Hypotha [PMID:41127649]	Govindarajulu M, Patel MY, Krishnan J, L	Neurotrauma reports	2023	0
Contextual generalization of social stress learning is modulated by orexin recep [PMID:35724928]	Yaeger JDW, Krupp KT, Summers TR, Summer	Neuropharmacology	2022	0
Evaluation of the α-casein (CSN1S1) locus as a potential target for a site-speci [PMID:35568783]	["Smirnov A", "Kontsevaya G", "Shnaider	Scientific reports	2022	0
Outcomes of a telemedicine bowel management program during COVID-19. [PMID:34686377]	["Knaus M", "Ahmad H", "Metzger G", "Bey	Journal of pediatric surgery	2022	0
Chemical genetic activation of the cholinergic basal forebrain hippocampal circu [PMID:35418161]	Weilin Liu, Jianhong Li, Minguang Yang	{'name': "Alzheimer's Research	2022	0
Sleep interventions in AD trials show inconsistent cognitive benefits, possibly [PMID:33661831]	Unknown	Sleep Medicine Reviews	2021	0
Insulin Resistance and Diabetes Mellitus in Alzheimer's Disease. [PMID:34069890]	Burillo J, Marqués P, Jiménez B, Gonzále	Cells	2021	0
Machine learning for clinical decision support in infectious diseases: a narrati [PMID:31539636]	["Peiffer-Smadja N", "Rawson T", "Ahmad	Clinical microbiology and infe	2020	0
Complexities of Understanding Function from CKD-Associated DNA Variants. [PMID:32513823]	["Lin J", "Susztak K"]	Clinical journal of the Americ	2020	0
Genetic deletion of trpa1 receptor attenuates amyloid beta- 1-42 (aβ1-42)-induce [PMID:32473171]	Maja Payrits, Éva Borbély, Soma Godo	{'name': 'Mechanisms of ageing	2020	0

Debates (15)

Multi-agent debates referencing this entity

Investigate mechanisms of epigenetic reprogramming in aging neurons, including D

closed · Rounds: 4 · Score: 0.50 · 2026-04-21

Investigate mechanisms of epigenetic reprogramming in aging neurons [TARGET_ART

closed · Rounds: 0 · Score: 0.50 · 2026-04-21

Investigate mechanisms of epigenetic reprogramming in aging neurons

closed · Rounds: 0 · Score: 0.56 · 2026-04-21

Investigate mechanisms of epigenetic reprogramming in aging neurons, including D

closed · Rounds: 0 · Score: 0.48 · 2026-04-21

Investigate mechanisms of epigenetic reprogramming in aging neurons, including D

closed · Rounds: 0 · Score: 0.51 · 2026-04-21

Investigate mechanisms of epigenetic reprogramming in aging neurons, including D

closed · Rounds: 4 · Score: 0.73 · 2026-04-21

Investigate mechanisms of epigenetic reprogramming in aging neurons, including D

closed · Rounds: 0 · Score: 0.52 · 2026-04-21

Mechanistic validation of SEA-AD differential expression hypotheses: Complement

closed · Rounds: 0 · Score: 0.66 · 2026-04-21

Investigate mechanisms of epigenetic reprogramming in aging neurons, including D

closed · Rounds: 0 · Score: 0.58 · 2026-04-21

Mechanistic validation of SEA-AD differential expression hypotheses: Complement

closed · Rounds: 0 · Score: 0.64 · 2026-04-21

Related Research

Hypotheses and analyses mentioning TAR in their description or question text

Closed-loop tACS targeting EC-II SST interneurons to block tau propagation and r

Score: 0.896 · Alzheimer's disease · 2026-04-05

## Mechanistic Overview Closed-loop tACS targeting EC-II SST interneurons to block tau propagation and restore perforant

Multi-Target Hypothesis: Aβ-Induced Cholinergic Damage is Partially Irreversible

Score: 0.887 · unknown disease · 2026-04-12

## Mechanistic Overview Multi-Target Hypothesis: Aβ-Induced Cholinergic Damage is Partially Irreversible starts from the

Closed-loop focused ultrasound targeting EC-II PV interneurons to restore theta-

Score: 0.863 · Alzheimer's disease · 2026-04-07

## Mechanistic Overview Closed-loop focused ultrasound targeting EC-II PV interneurons to restore theta-gamma coupling a

Closed-loop tACS targeting EC-II PV interneurons to suppress burst firing and bl

Score: 0.857 · Alzheimer's disease · 2026-04-05

## Mechanistic Overview Closed-loop tACS targeting EC-II PV interneurons to suppress burst firing and block tau propagat

Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation

Score: 0.841 · neurodegeneration · 2026-04-02

## Mechanistic Overview Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation starts from the claim t

Closed-loop tACS targeting EC-II parvalbumin interneurons to restore gamma rhyth

Score: 0.831 · Alzheimer's disease · 2026-04-05

## Mechanistic Overview Closed-loop tACS targeting EC-II parvalbumin interneurons to restore gamma rhythmogenesis and bl

Real-time gamma-guided transcranial focused ultrasound targeting EC-II SST inter

Score: 0.827 · Alzheimer's disease · 2026-04-07

## Mechanistic Overview Real-time gamma-guided transcranial focused ultrasound targeting EC-II SST interneurons to resto

Beta-frequency entrainment therapy targeting PV interneuron-astrocyte coupling f

Score: 0.827 · Alzheimer's disease · 2026-04-05

## Mechanistic Overview Beta-frequency entrainment therapy targeting PV interneuron-astrocyte coupling for tau clearance

Targeting the Mechanistic Link Between AQP4 Dysfunction and Ferroptosis Prevents

Score: 0.803 · neurodegeneration · 2026-04-17

## Mechanistic Overview Targeting the Mechanistic Link Between AQP4 Dysfunction and Ferroptosis Prevents Both Cytotoxic

pH-Sensitive Bispecific Antibody Targeting Transferrin Receptor for CNS Delivery

Score: 0.800 · neurodegeneration · 2026-04-22

## Mechanistic Overview pH-Sensitive Bispecific Antibody Targeting Transferrin Receptor for CNS Delivery starts from the

Closed-loop transcranial focused ultrasound targeting CA1 PV interneurons with r

Score: 0.797 · Alzheimer's disease · 2026-04-07

## Mechanistic Overview Closed-loop transcranial focused ultrasound targeting CA1 PV interneurons with real-time gamma f

Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)

Score: 0.795 · neurodegeneration · 2026-04-02

## Mechanistic Overview Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs) starts from the claim t

Targeting SASP-Complement Amplification Through HIF-1α Downstream Effectors

Score: 0.793 · neurodegeneration · 2026-04-14

## Mechanistic Overview Targeting SASP-Complement Amplification Through HIF-1α Downstream Effectors starts from the clai

Closed-loop tACS targeting entorhinal cortex layer II SST interneurons to activa

Score: 0.784 · Alzheimer's disease · 2026-04-05

## Mechanistic Overview Closed-loop tACS targeting entorhinal cortex layer II SST interneurons to activate AMPK-autophag

Targeted APOE4-to-APOE3 Base Editing Therapy

Score: 0.758 · neurodegeneration · 2026-04-02

**Molecular Mechanism and Rationale** The apolipoprotein E4 (APOE4) variant represents the most significant genetic ris

TAR

Understanding Entity Pages

Summary

Wiki Pages (13)

TARDBP Protein (TDP-43)

TAR DNA-Binding Protein 43 (TDP-43)

TDP-43 (TAR DNA-Binding Protein 43) - Biomarker

Synaptic Therapy Alzheimer's Research Trial (START): A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease (NCT05531656)

SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment

TARS1 — Threonyl-tRNA Synthetase 1

TARDBP — TAR DNA Binding Protein 43

CACNG6 (TARP γ8)

TARDBP/TDP-43 Protein

ALS10 - Amyotrophic Lateral Sclerosis 10 (TARDBP)

TARDBP Mutations in Amyotrophic Lateral Sclerosis

CACNG4 - TARP Gamma-4 Calcium Channel Subunit

STAR — Steroidogenic Acute Regulatory Protein

Pathway Diagram

Outgoing (59)

Incoming (102)

Targeting Hypotheses (30)

Mentioning Analyses (9)

Does APOE4 drive tau propagation

Does APOE4 drive tau propagation

test debate

Do these mechanistic hypotheses from the SEA-AD Atlas bundle explain layer-speci

Do these mechanistic hypotheses explain layer-specific synaptic vulnerability in

Mechanistic validation of SEA-AD differential expression hypotheses: Complement

Investigate mechanisms of epigenetic reprogramming in aging neurons, including D

Investigate mechanisms of epigenetic reprogramming in aging neurons, including D

Investigate mechanisms of epigenetic reprogramming in aging neurons

Experiments (11)

Related Papers (20)

Debates (15)

Investigate mechanisms of epigenetic reprogramming in aging neurons, including D

Investigate mechanisms of epigenetic reprogramming in aging neurons [TARGET_ART

Investigate mechanisms of epigenetic reprogramming in aging neurons

Investigate mechanisms of epigenetic reprogramming in aging neurons, including D

Investigate mechanisms of epigenetic reprogramming in aging neurons, including D

Investigate mechanisms of epigenetic reprogramming in aging neurons, including D

Investigate mechanisms of epigenetic reprogramming in aging neurons, including D

Mechanistic validation of SEA-AD differential expression hypotheses: Complement

Investigate mechanisms of epigenetic reprogramming in aging neurons, including D

Mechanistic validation of SEA-AD differential expression hypotheses: Complement

Related Research

Closed-loop tACS targeting EC-II SST interneurons to block tau propagation and r

Multi-Target Hypothesis: Aβ-Induced Cholinergic Damage is Partially Irreversible

Closed-loop focused ultrasound targeting EC-II PV interneurons to restore theta-

Closed-loop tACS targeting EC-II PV interneurons to suppress burst firing and bl

Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation

Closed-loop tACS targeting EC-II parvalbumin interneurons to restore gamma rhyth

Real-time gamma-guided transcranial focused ultrasound targeting EC-II SST inter

Beta-frequency entrainment therapy targeting PV interneuron-astrocyte coupling f

Targeting the Mechanistic Link Between AQP4 Dysfunction and Ferroptosis Prevents

pH-Sensitive Bispecific Antibody Targeting Transferrin Receptor for CNS Delivery

Closed-loop transcranial focused ultrasound targeting CA1 PV interneurons with r

Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)

Targeting SASP-Complement Amplification Through HIF-1α Downstream Effectors

Closed-loop tACS targeting entorhinal cortex layer II SST interneurons to activa

Targeted APOE4-to-APOE3 Base Editing Therapy